

1 **No support for oxytocin modulation of reward-related brain function in autism:**  
2 **evidence from a randomized controlled trial**

3

4 **Authors**

5 Annalina V. Mayer (1,2)\*, Katrin Preckel (3), Kristin Ihle (3), Fabian A. Piecha (3), Klaus Junghanns (2),  
6 Stefan Reiche (2), Lena Rademacher (1,2), Inge Kamp-Becker (4,5), Sanna Stroth (4,5), Stefan Roepke  
7 (6), Charlotte Küpper (7), Veronika Engert (3,8), Tania Singer (9), Philipp Kanske(3,10), Frieder M.  
8 Paulus (1,2), Sören Krach (1,2)

9 \* Corresponding author

10

11 **Affiliations**

12 1 Social Neuroscience Lab, Department of Psychiatry and Psychotherapy, University of Lübeck, Lübeck,  
13 Germany

14 2 Translational Psychiatry Unit (TPU), Department of Psychiatry and Psychotherapy, University of  
15 Lübeck, Germany

16 3 Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany

17 4 Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, Philipps  
18 University of Marburg, Marburg, Germany

19 5 Marburg Center for Mind, Brain and Behavior (MCMBB), Philipps University of  
20 Marburg, Marburg, Germany

21 6 Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin,  
22 Campus Benjamin Franklin, Berlin, Germany

23 7 Social Cognition Group, Berlin School of Mind and Brain, Department of Psychology, Humboldt-  
24 Universität zu Berlin, Berlin, Germany

25 8 Institute of Psychosocial Medicine and Psychotherapy, Jena University Hospital, Friedrich-Schiller  
26 University, Jena, Germany

27 9 Social Neuroscience Lab, Max Planck Society, Berlin, Germany

28 10 Clinical Psychology and Behavioral Neuroscience, Faculty of Psychology, Technische Universität  
29 Dresden, Dresden, Germany

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30

1 **Corresponding author**

2 Annalina V. Mayer

3 Social Neuroscience Lab

4 Center of Brain, Behavior, and Metabolism (CBBM)

5 Universität zu Lübeck

6 Ratzeburger Allee 160

7 23562 Lübeck

8 Phone: +49 451 3101 7530

9 Email: [ann.mayer@uni-luebeck.de](mailto:ann.mayer@uni-luebeck.de)

10

11 **Short title: Intranasal oxytocin and reward in autism**

1 **Abstract**

2 Autism spectrum disorder (ASD) is characterized by difficulties in social communication and interaction,  
3 which have been related to atypical neural processing of rewards, especially in the social domain. Since  
4 intranasal oxytocin has been shown to modulate activation of the brain's reward circuit, oxytocin could  
5 be a useful tool to ameliorate the processing of social rewards in ASD and thus improve social difficulties.  
6 In this randomized, double-blind, placebo-controlled, crossover fMRI study, we examined effects of a  
7 24 IU dose of intranasal oxytocin on reward-related brain function in 37 men with an ASD diagnosis and  
8 37 age- and IQ-matched control participants. Participants performed an incentive delay task that allows  
9 the investigation of neural activity associated with the anticipation and receipt of monetary and social  
10 rewards. Apart from a specific interaction effect in a single voxel within the left amygdala during the  
11 receipt of rewards, oxytocin did not influence neural processes related to the anticipation or consumption  
12 of social or monetary rewards in either group. Exploratory analyses suggested that oxytocin may  
13 increase ventral striatum sensitivity to monetary, but not social rewards, in individuals with high levels  
14 of self-reported anxiety, depression, alexithymia, and autistic traits irrespective of an ASD diagnosis.  
15 There were no significant differences in reward-related brain function between the two groups under  
16 placebo. Overall, our results do not support the hypothesis that intranasal oxytocin generally enhances  
17 activation of reward-related neural circuits in men with and without ASD without intellectual impairment.  
18 How and if oxytocin can be beneficial in the treatment of social difficulties in ASD needs to be addressed  
19 by examining moderating influences of individual differences and context on reward-related oxytocin  
20 effects.

21

## 1 Introduction

2 Difficulties in social communication and interaction are at the core of autism spectrum disorder (ASD).  
3 For example, children with autism show low levels of eye contact [1], rarely point at objects to initiate  
4 joint attention [2,3], and may struggle to build and maintain friendships [4]. It has been hypothesized that  
5 these difficulties relate to a diminished sensitivity to social rewards, such as smiles, praise, or gestures  
6 of approval, which leads to a lack of orienting toward social stimuli [5–7]. While behavioral and  
7 psychophysiological studies seem to support this notion and often highlight diminished responsiveness  
8 particularly to social rewards in individuals with ASD [8–12], neuroimaging studies indicate reduced  
9 responses of reward-related brain circuits to both social and non-social rewards (e.g., money),  
10 compared to individuals without an ASD diagnosis [13,14]. Specifically, meta-analytic evidence shows  
11 robust hypoactivation in the caudate nucleus, the nucleus accumbens located in the ventral striatum,  
12 and the anterior cingulate cortex across a variety of reward tasks [14]. These regions are considered  
13 key structures within the “reward circuit” [15–17]. This complex circuit consists of several striatal, cortical  
14 and midbrain regions, as well as amygdala, hippocampus and specific brainstem structures, and is  
15 thought to be a central component underlying the development and control of motivated behaviors [15–  
16 17].

17 In the last fifteen years, the hormone and neuropeptide oxytocin has gained attention in the fields of  
18 psychiatry and social neuroscience as a modulator of social cognition and behavior [18–22]. Importantly,  
19 studies in mice have demonstrated that oxytocin plays a crucial role in the processing of social rewards  
20 through coordinated activity with serotonin in the nucleus accumbens [23] and by regulating dopamine  
21 release in midbrain structures during social interactions [24,25]. In humans, results from functional brain  
22 imaging studies suggest that intranasally administered oxytocin can influence neural activity of regions  
23 within the reward circuit. For example, oxytocin administration has been shown to increase neural  
24 responses to social [26] as well as non-social rewards in the midbrain [27], anterior cingulate cortex and  
25 caudate nucleus [28], and to increase perfusion of the nucleus accumbens while viewing pictures of  
26 faces [29]. Further evidence for a role of oxytocin in reward processing is provided by investigations of  
27 oxytocin receptor distribution in the human brain, showing that oxytocin receptors are located in regions  
28 of the reward circuit such as the amygdala, anterior cingulate cortex and brainstem areas, among others  
29 [30]. Moreover, a recent study demonstrated that genes involved in the oxytocin pathway are highly  
30 expressed in regions that are associated with reward, motivation and learning [31].

1 With oxytocin being involved in a range of social behaviors [32], it has been suggested that variation in  
2 the oxytocin system contributes to the etiology of ASD [33]. A growing body of literature indicates  
3 associations of blood oxytocin levels [34–39] and oxytocin pathway genes with the degree of social  
4 difficulties or the diagnosis of ASD per se [40–42]. This evidence has led to a rising interest in intranasal  
5 oxytocin as a potential treatment of social symptoms in ASD. Several clinical trials have investigated the  
6 effects of a single or repeated doses of oxytocin, to date with overall inconclusive results [43,44].  
7 However, clinical studies using functional magnetic resonance imaging (fMRI) suggest that oxytocin  
8 may influence regions within the reward circuit in autistic individuals. For example, it has been shown  
9 that oxytocin administration enhanced activity in the striatum and prefrontal cortex areas in children with  
10 ASD during judgments of social and non-social images, with significantly greater striatal activity during  
11 the social vs. non-social task [45]. Another study demonstrated increased connectivity between the  
12 nucleus accumbens and cortical regions of the reward circuit after oxytocin administration during two  
13 tasks involving social stimuli [46].

14 To date, only two imaging studies have examined oxytocin effects on reward processing in ASD more  
15 directly and have yielded contradictory results. One study testing men with ASD without intellectual  
16 impairment reported that intranasal oxytocin specifically increased learning from *social* cues and  
17 reinforcement, which was accompanied by a stronger association of reward prediction errors and  
18 nucleus accumbens activity compared to placebo [47]. In contrast, another study in children with ASD  
19 without intellectual impairment found enhanced activity within regions of the reward circuit only during  
20 the anticipation of *non-social* rewards after oxytocin administration [48]. Overall, little is known about the  
21 influence of oxytocin on the processing of social vs. non-social rewards in individuals with ASD.  
22 Important questions such as whether this potential influence is similar or different in individuals without  
23 ASD, and which experimental (e.g., reinforcement learning vs. reward anticipation) and individual factors  
24 (e.g., personality, degree of social difficulties, age) might contribute to its efficacy, remain to be  
25 answered.

26 To address these open questions, we conducted a randomized, double-blind, placebo-controlled,  
27 crossover fMRI study examining the effect of a single dose of oxytocin on reward-related brain function  
28 in 37 men with an ASD diagnosis without intellectual impairment and 37 age- and IQ-matched control  
29 participants. Participants performed a well-established incentive delay task that allows an investigation  
30 of neural activity associated with the anticipation and receipt of monetary and social rewards [49–51].

1 The incentive delay task was embedded in a multi-center trial with the overall goal to compare oxytocin  
2 effects across different facets of social cognition and affect [52,53]. We hypothesized that participants  
3 with ASD, compared to control participants without ASD, would show less pronounced activity within  
4 regions of the reward circuit under placebo, specifically during social reward anticipation and  
5 consumption. Further, we assumed that oxytocin would trigger an increase in reward-related brain  
6 function in ASD, accompanied by faster response times during the anticipation of especially social  
7 rewards. The assessed measures of reward sensitivity were consequently expected to be comparable  
8 to those of the control group under placebo.

## 9 **Methods and Materials**

### 10 *Participants*

11 Participants were enrolled at the University of Lübeck/University Hospital Schleswig-Holstein in Lübeck  
12 and the Max-Planck Institute for Human Cognitive and Brain Sciences in Leipzig between December  
13 2016 and January 2019 ( $n_{\text{Lübeck}} = 24$ ,  $n_{\text{Leipzig}} = 50$ ). The sample consisted of 37 men with a confirmed  
14 ICD-10 diagnosis of Asperger's syndrome ( $n = 28$ ), infantile autistic disorder ( $n = 6$ ), or atypical autism,  
15 ( $n = 3$ ) and 37 healthy male control participants that were matched one-on-one for age ( $\pm 7$  years) and  
16 full-scale IQ ( $\pm 7$  IQ-points on the Wechsler Adult Intelligence Scale [54], see Table 1). Eligible  
17 participants were German native speakers between 19 and 40 years of age. We excluded participants  
18 with an IQ lower than 70, a BMI less than 18 or over 30, those with a frequent use of drugs, alcohol and  
19 nicotine (more than 15 cigarettes per day), those with current suicidal tendencies, contraindications to  
20 oxytocin (e.g. cardiac arrhythmia), metal implants or any other MRI contraindications, as well as  
21 participants who were not able to give consent. Participants receiving concurrent antidepressant ( $n = 2$ )  
22 or other medication ( $n = 2$ ) were required to keep the dosage constant during participation. Participants  
23 with ASD were recruited from five university centers offering autism specific diagnosis and counselling  
24 across Germany, as well as through online advertisements and leaflets. In the specialized university  
25 centers, participants with ASD had undergone standardized diagnostic procedures including the Autism  
26 Diagnostic Observation Schedule (ADOS [55]) and the Autism Diagnostic Interview-Revised if parental  
27 informants were available (ADI-R [56]; caregivers were available in 70.3% of all cases). Participants with  
28 ASD who were not referred directly from an autism specific university center were required to provide a  
29 report detailing the diagnostic process of their ASD diagnosis (i.e., whether the diagnosis was based on  
30 gold standard diagnostic procedures including ADI-R and ADOS) and a confirmation of their ASD

1 diagnosis based on ICD-10 criteria. Control participants were recruited through in-house databases and  
 2 from the general population via public notices and online advertisements. Additional exclusion criteria  
 3 for control participants included a history of neurological, endocrinological or psychiatric disorders based  
 4 on self-report, current psychotherapeutic or psychiatric treatment, current use of psychotropic  
 5 medication, first- or second-degree relatives with autism spectrum disorders, and a score of 32 or higher  
 6 on the Autism-Spectrum Quotient (AQ) [57]. This study was approved by the Ethics Committee of the  
 7 University of Lübeck, Germany (AZ 15-337) and the German Federal Institute for Drugs and Medical  
 8 Devices (Bundesinstitut für Arzneimittel und Medizinprodukte; BfArM; Gz: 61-3910-4041063) in Bonn,  
 9 Germany, and was carried out in compliance with the Declaration of Helsinki of 1975, as revised in 2008.  
 10 Full informed written consent was obtained from all participants.

11 Details on a priori sample size calculations are given in our published study protocol [52]. Briefly, based  
 12 on meta-analytic effect size estimates available at the time of study planning, we assumed relatively  
 13 strong effects of oxytocin treatment on neural network activity ( $d = 0.65$ ). A sample of  $n = 88$  participants  
 14 with ASD (and  $n = 88$  control participants) would be necessary to reach a desired power of 80% at a  
 15 significance level of  $\alpha = 0.001$  for two-tailed t-test comparisons of oxytocin effects in a 2x2 cross-over  
 16 design. Because of difficulties with patient recruitment and resulting significant time delays, the study  
 17 had to be ended prematurely. Of the enrolled  $n = 74$  participants, one control participant discontinued  
 18 the study after the first MRI session, leaving data from  $n = 73$  participants to be analyzed (supplementary  
 19 Figures S1 and S2).

20 **Table 1:** Sample characteristics.

	ASD ( $N = 37$ )		Control ( $N = 36$ )		95% Confidence Interval	
	$n$	$M \pm SD$	$M \pm SD$	Cohen's $d$	lower	upper
Comorbidities						
ADHD	1					
SDD-MF	2					
DWE	1					
ADOS Total <sup>1</sup>		11.5 ± 4.5				
ADOS SA <sup>2</sup>		11.6 ± 4.6				
ADOS RRB <sup>3</sup>		2.1 ± 2.5				
Age		26.2 ± 4.7	27.1 ± 4.4	-0.20	-0.66	0.26
BMI		24.3 ± 3.8	23.2 ± 2.7	0.33	-0.14	0.80
Full-scale IQ (WAIS IV)		106.9 ± 14.2	109.3 ± 12.3	-0.19	-0.65	0.28
Verbal IQ (WST)		110.2 ± 13.8	112.6 ± 12.3	-0.19	-0.65	0.28

AQ	30.3 ± 9.2	15.0 ± 4.8	2.08	1.41	2.73
IRI Empathy Score	60.5 ± 15.1	72.1 ± 9.1	-0.92	-1.43	-0.40
TAS-20	47.6 ± 12.1	38.0 ± 8.3	0.92	0.41	1.42
BVAQ	116.0 ± 23.2	113.0 ± 19.0	0.14	-0.33	0.61
BDI-II	5.5 ± 5.2	4.0 ± 4.8	0.30	-0.17	0.76
SIAS	33.4 ± 16.3	20.4 ± 12.0	0.90	0.39	1.40
STAI-T	43.8 ± 10.4	35.0 ± 8.6	0.92	0.41	1.43

*Note.* Information on comorbidities was provided by the referring clinics and university centers and were not additionally assessed or validated at the study centers. ADHD = attention deficit hyperactivity disorder, SDD-MF = specific developmental disorder of motor function, DWE = disorder of written expression, ADOS = Autism Diagnostic Observation Schedule, ADOS SA = ADOS social affect score, ADOS RRB = ADOS repetitive and restricted behavior score, BMI = body mass index, WAIS IV = Wechsler Adult Intelligence Scale IV, WST = Wortschatztest, AQ = Autism Spectrum Quotient, IRI = Interpersonal Reactivity Index, empathy score (sum score excluding “personal distress” subscale), TAS-20 = Twenty-Item Toronto Alexithymia Scale, BVAQ = Bermond-Vorst Alexithymia Questionnaire, BDI-II = Beck Depression Inventory, SIAS = Social Interaction Anxiety Scale, STAI-T = State-Trait Anxiety Inventory – trait. <sup>1</sup>data available from  $n = 34$  participants, <sup>2</sup>data available from  $n = 31$  participants, <sup>3</sup>data available from  $n = 21$  participants.

## 1 *Trial Design*

2 This clinical trial was registered in the German Clinical Trial Register (registration number:  
3 DRKS00010053) on the 8th of April 2016.

4 This multi-center clinical trial used a randomized, double-blind, placebo-controlled, cross-over protocol.  
5 After an initial screening procedure, eligible participants were invited to three visits at the respective  
6 study site. During the first visit, all participants received detailed medical information on intranasal  
7 oxytocin and the MRI assessment, after which informed written consent was obtained. Participants with  
8 ASD were then randomly allocated to a treatment arm determining the order of treatment (oxytocin  
9 first/placebo first). Details on randomization and blinding are given in supplementary methods. Control  
10 participants were assigned to the same treatment arms as the participants they were matched to. During  
11 the second and third visit, participants received a single dose of oxytocin or placebo intranasally and  
12 took part in three independent experiments in the MRI scanner starting approximately 40 minutes after  
13 substance administration. Except for the administered nasal spray, the second and third visit included  
14 identical procedures and measurements. The visits were 14 days apart to provide a sufficiently long  
15 wash-out period.

## 16 *Procedure*

17 Interested participants were first screened for main inclusion criteria. For interested control participants,  
18 this screening consisted of a short telephone interview, as well as the completion of the Wechsler Adult  
19 Intelligence Scale (WAIS-IV) [54] at the respective study site. If a control participant was matched with




1 an already randomized participant with ASD, he was invited to the first study visit. For interested  
2 participants with ASD, successful telephone screening was directly followed by the first study visit. In  
3 preparation for the first visit, participants received a copy of the informed consent to read. During the  
4 first visit, a study physician gave detailed information on risks and benefits of the study and answered  
5 the participant's questions. Following written consent, a study nurse ensured that all inclusion and no  
6 exclusion criteria were met. For this purpose, heart rate and blood pressure were measured, and MRI  
7 compatibility was assessed using a questionnaire. A brief standardized interview was conducted to  
8 exclude possible alcohol abuse or dependence. Subsequently, patients and control participants filled  
9 out several health and personality related questionnaires. These included the Toronto Alexithymia Scale  
10 (TAS 20) [58,59], the Beck Depression Inventory (BDI-II) [60,61] and the Autism Spectrum Quotient  
11 (AQ) [57]. Further, the WAIS-IV [54] was administered to participants with ASD to obtain a valid estimate  
12 of full-scale IQ. All participants were instructed to abstain from food, caffeine, and excessive amounts  
13 of water 2 hours before the beginning of the next two study visits.

14 At the beginning of the second and third visits it was ensured that none of the inclusion or exclusion  
15 criteria had changed since the last visit. To monitor potential cardiovascular effects of oxytocin, heart  
16 rate and blood pressure were measured several times during these visits, starting with two baseline  
17 measurements at the beginning of each session. Next, participants were asked to provide a saliva  
18 sample for cross-sectional (epi)genetic analyses conducted within the multi-center consortium on ASD  
19 [53]. Subsequently, under the guidance of an investigator, participants self-administered 12 puffs of the  
20 nasal spray (6 puffs per nostril, each containing 2 IU) over the course of several minutes. A third and  
21 fourth measurement of blood pressure and heart rate followed nasal spray administration. Further,  
22 current feelings of anxiety were assessed using the state scale of the State Trait Anxiety Inventory  
23 (STAI-S) [62]. Approximately 40 minutes after substance administration, participants entered the  
24 scanner and performed three independent experiments, which took about 90 minutes. The reward  
25 experiment was one of these three experiments. Results from the other two tasks, which are described  
26 in our published study protocol [52], will be reported separately. Details on the average latency between  
27 substance administration and start of the reward experiment are given in supplementary Table S1.  
28 Immediately after the MRI session, blood pressure and heart rate were measured twice, and participants  
29 once again indicated their current state of anxiety using the STAI-S. At the end of each session,  
30 participants were asked to guess whether they had received oxytocin or placebo. In total, the second  
31 and third visits lasted about 2.5 to 3 hours.

1 To assess additional relevant health and personality measures, participants were asked to fill out several  
 2 online questionnaires between the second and third visit. These included, among others, the  
 3 Interpersonal Reactivity Index (IRI) [63,64], the Social Interaction Anxiety Scale (SIAS) [65], the State-  
 4 Trait Anxiety Inventory – trait (STAI-T) [62] and the Bermond-Vorst Alexithymia Questionnaire (BVAQ)  
 5 [66]. A complete list of all questionnaires that were assessed but not used in the current data analysis  
 6 is provided in supplementary methods.  
 7 Subjective side effects were assessed by directly asking participants if they had experienced any health-  
 8 related problems after the second and third visit. Participants were instructed to contact the study team  
 9 in case of subjectively experienced side effects up to two weeks after substance administration. No side  
 10 effects were reported.

11 *Task and Stimuli*



**Figure 1:** The monetary and social incentive delay paradigm (MID/SID). *A:* Timing of the task. Participants were asked to hit a button as fast as possible when the target appeared on the screen. Sufficiently fast responses were followed by an image of either a face or a wallet. Blurred images were shown when responses were too slow. *B:* Social and monetary outcome stimuli and associated cues. To create a reward anticipation phase, a cue indicating the outcome for sufficiently fast responses was presented before the target. Circle cues signaled pictures of wallets, while squares signaled pictures of faces.

1 The monetary and social incentive delay paradigm (MID/SID) was one of three tasks that participants  
2 performed in the scanner. The MID [51] and its adaptation SID [49,50] are well-established paradigms  
3 that are used to examine an individual's neural response to the anticipation and consumption of  
4 monetary or social rewards. In the current study, 36 MID and 36 SID trials were mixed and presented in  
5 a pseudo-randomized order within a single experiment. During the task, participants were required to  
6 press a button whenever a target symbol appeared on the screen. Sufficiently fast responses were  
7 followed by a picture of either a face (SID) or a wallet (MID). Blurred pictures were shown when the  
8 reaction was too slow (Fig. 1A). Task difficulty was standardized to a hit rate of ~66% by adjusting the  
9 time window for responses to individual response times. A first estimate of individual response times  
10 was calculated during a training phase at the beginning of the experiment, and the time window was  
11 continuously adjusted to the participant's performance during the main experiment. In the main  
12 experiment, cues preceding the target indicated which type of picture was going to be presented after a  
13 sufficiently fast response (Fig. 1B). Circles signaled pictures of wallets and squares signaled pictures of  
14 faces. Horizontal lines within the circles and squares further indicated whether or not the picture would  
15 contain a reward: three lines signaled a smiling face (social reward) or a wallet filled with coins (monetary  
16 reward); a single line signaled a face with a neutral expression or an empty wallet (no reward). For the  
17 face stimuli, 26 color photographs displaying 2 different expressions of 13 people (7 female, 6 male)  
18 were taken from the NimStim set of Facial Expressions [67]. The money stimuli consisted of 28 self-  
19 created color photographs displaying 14 different wallets, each once empty and once filled with coins.  
20 Before entering the scanner, participants received detailed instructions on the task and were  
21 encouraged to respond as fast as possible to all cue types. A brief test run consisting of 5 trials ensured  
22 that the instructions were understood correctly. During the two MRI sessions, parallel versions of the  
23 task were used, each with different stimuli.

24 The experiment was run using the software Presentation® (Neurobehavioral Systems, Inc., San  
25 Francisco, CA). Stimuli were presented on a screen positioned behind the MRI that participants viewed  
26 through a mirror mounted to the head coil. Participants responded to the target by pressing a button on  
27 a fiberoptic response box with the index finger of their right hand. Response times were recorded. At  
28 one study site (Leipzig), fMRI assessment was accompanied by eye-tracking and measurements of  
29 heart rate, respiration, and skin conductance, which will be analyzed and reported separately. The total

1 experiment, including a brief training phase at the beginning to determine the participant's average  
2 reaction time, lasted about 15 minutes.

### 3 *fMRI Data Acquisition*

4 Participants were scanned using a 3T Siemens MAGENTOM Skyra scanner (Siemens, Erlangen,  
5 Germany) at the Center of Brain, Behavior, and Metabolism (CBBM) at the University of Lübeck and a  
6 3T Siemens MAGNETOM Skyra fit scanner (Siemens, Erlangen, Germany) at the Max-Planck Institute  
7 for Human Cognitive and Brain Sciences in Leipzig. An echo planar imaging (EPI) sequence was used  
8 for the acquisition of functional volumes (number of slices = 50, voxel size =  $3 \times 3 \times 3 \text{ mm}^3$ , FoV =  $210$   
9  $\times 210 \text{ mm}^2$ , TR = 2000 ms, TE = 27 ms,  $90^\circ$  flip angle). Simultaneous multi-slice imaging (slice  
10 acceleration factor = 2) was used for accelerated coverage of the whole brain. A high-resolution  
11 anatomical image was acquired for normalization using a T1-weighted 3D MPRAGE sequence (number  
12 of slices = 176 (sagittal), voxel size =  $1 \times 1 \times 1 \text{ mm}^3$ , FoV =  $240 \times 256 \text{ mm}^2$ , TR = 2300 ms, TE Lübeck  
13 = 5.49 ms, TE Leipzig = 5.52 ms,  $9^\circ$  flip angle).

### 14 *Data Analysis*

#### 15 *Behavioral Data*

16 Behavioral data including response times and hit rates were analyzed using Jamovi version 1.2.27 [68]  
17 and R version 4.0.3 [69]. Trials with response times below 100 ms and above 2000 ms were excluded  
18 from the analysis. Mean response times and hit rates were computed for each subject, session, and  
19 task condition. Since mean response times were positively skewed, we applied a log transformation  
20 [70].

21 Effects of treatment, group and task conditions on mean response times were examined using a  
22 repeated-measures general linear model (GLM). Within-subject factors included task type (money vs.  
23 social), reward intensity (reward vs. no reward), and treatment (oxytocin vs. placebo). Group (ASD vs.  
24 controls) was entered as a between-subject factor. Further, site (Leipzig vs. Lübeck), treatment arm  
25 (oxytocin first vs. placebo first) and order of the incentive delay task within the three sub-experiments  
26 (1, 2 or 3) were included in the model as between-subject factors to control for these possible confounds.

27 In an exploratory approach, we analyzed interactions of treatment and several variables capturing  
28 interindividual differences, including age, IQ, anxiety (STAI-T and SIAS sum scores), depression (BDI-  
29 II sum score), autistic traits (AQ sum score), empathy (IRI sum score of subscales *empathic concern*,

1 *perspective taking* and *fantasy*), and alexithymia (TAS-20 and BVAQ sum scores) on mean response  
2 times. First, as a measure of individual reward sensitivity, we calculated differences in response times  
3 for reward and no reward trials for social and monetary cues, respectively (money: no reward-reward  
4 and social: no reward-reward). This was done separately for the oxytocin and placebo sessions. Next,  
5 all variables of interest were correlated with behavioral reward sensitivity under oxytocin and placebo  
6 using Spearman's rho as a non-parametric measure of rank correlation. For each variable of interest,  
7 the resulting two correlation coefficients were then compared using the approach for dependent  
8 overlapping correlations proposed by Steiger [71] as implemented in the cocor R package [72].

9 To examine possible anxiolytic effects of oxytocin, we calculated a repeated-measures GLM with state  
10 anxiety (measured with STAI-S) as the dependent variable. Treatment and time (pre-scan vs. post-scan)  
11 were entered as within-subject factors, and group, site, and treatment arm were entered as between-  
12 subject factors.

13 A binomial test was used to determine whether participants were able to identify above chance level  
14 which nasal spray they had received. Since some participants indicated the same treatment at both  
15 sessions, we compared the proportion of correct guesses per treatment across both sessions to 0.5,  
16 instead of analyzing correct guesses per session. For the binomial tests, Bayes factors are provided in  
17 addition to the p-values as indicators of evidence for and against the alternative hypothesis.

### 18 *Imaging Data*

19 Because of an unexpected loss of fMRI data from one session, one patient was excluded from the  
20 analyses. Another patient was excluded due to excessive head motion. fMRI data from the remaining  $n$   
21 = 35 patients and  $n = 36$  control participants were analyzed using SPM12 [73] in MATLAB R2019b [74].  
22 Since the length of the experiment varied according to the subjects' mean response times, the MRI  
23 measurements were terminated manually, which led to variance in the total number of images in the  
24 timeseries. The images to be analyzed were defined as all images up to two seconds after the end of  
25 the last trial, resulting in 381-383 images per subject and session. The functional volumes were slice-  
26 time corrected, spatially realigned, and normalized using the forward deformation fields as obtained from  
27 the unified segmentation of the anatomical T1 image. To remove low frequency drifts, the images were  
28 high pass filtered at 1/128 Hz.

1 Statistical analyses were performed on unsmoothed data in a two-level, mixed-effects procedure. The  
2 first-level general linear model (GLM) for each subject and session included a total of ten regressors of  
3 interest defining the onsets and durations of the four task conditions during the anticipation phase  
4 (social:reward, social:no reward, money:reward, money:no reward), the four task conditions during the  
5 feedback phase of successful trials (hits) and the onsets and durations of trials of the two task types  
6 (money vs. social) during the feedback phase of unsuccessful trials (misses). In addition, the six  
7 realignment parameters obtained during preprocessing as well as their first derivatives were included  
8 as regressors of no interest to account for noise due to head motion. To further reduce the influence of  
9 motion-related artifacts, we used the RobustWLS toolbox [75] to estimate the variance of the noise for  
10 each image in the time series and obtain a weighted least squares estimate of the regression  
11 parameters. Further, due to slightly different hardware and software configurations during image  
12 acquisition at the two study sites, the functional images showed differently distributed luminance values.  
13 To prevent signal dropout due to these differences, the implicit masking threshold of the linear models  
14 on the first level was lowered to 0.3 (default value in SPM 12: 0.8). Contrast images resulting from the  
15 first-level analyses were spatially smoothed with an 8 mm full-width half-maximum isotropic Gaussian  
16 kernel before being used in the analyses on the second level.

17 Several repeated-measures GLMs were implemented on the second level to examine the influence of  
18 treatment (oxytocin vs. placebo) and group (ASD vs. controls) on task-related brain activation. For this  
19 purpose, we created separate GLMs for each of the following first-level contrast images: main effect of  
20 reward intensity (reward > no reward), main effect of task type (social > money), and interaction effect  
21 of reward intensity  $\times$  task type, for both the anticipation and feedback phase (hits only), respectively.  
22 Each linear model contained treatment as within-subject factor, and group as between-subject factor.  
23 To account for potential variance due to differences in image acquisition, site was entered as covariate.  
24 In each model, we also controlled for treatment arm (oxytocin first vs. placebo first) as well as the order  
25 of the reward incentive delay task within the three sub-experiments (1, 2 or 3). First, we examined the  
26 respective average task effect across groups and treatments. Second, we compared task-related brain  
27 activation of the ASD and control group under the placebo condition. Third, we examined effects of  
28 oxytocin treatment across both groups. Fourth, we examined interaction effects of group and treatment  
29 to assess whether the magnitude of oxytocin effects depended on group.

30 *Regions of interest and whole-brain analyses*

1 To increase the sensitivity of our analyses, we first examined all effects in a priori defined regions of  
2 interest (ROI), which were defined separately for the anticipation and outcome phases. The ventral  
3 striatum was chosen as region of interest for the anticipation phase due to its pivotal role in reward  
4 processing, especially during the anticipation of rewards [51,76,77]. The bilateral ventral striatum mask  
5 consisted of two 8 mm spheres around peak coordinates (MNI coordinates left: -10, 10, -2; right: 12, 14,  
6 -4) from a meta-analysis of ventral striatum activation associated with reward anticipation [78]. For the  
7 outcome phase, the amygdala was chosen as region of interest because of its associations with reward  
8 consumption [49] and intranasal oxytocin effects [79,80]. A bilateral anatomical amygdala mask was  
9 created using the automated anatomic labeling atlas (AAL) [81] integrated in the WFU PickAtlas [82]  
10 (dilation factor one). All analyses were thresholded at a voxel level of  $p < .05$ , family-wise error (FWE)-  
11 corrected for multiple comparisons within the respective masks.

12 All contrasts of interest were also explored in the whole brain. A whole-brain mask was used to restrict  
13 the analyses to within-brain voxels, since signal from non-brain tissue was sometimes included in the  
14 contrast images due to the liberal analysis threshold on the first level. This mask was obtained by  
15 calculating average images of normalized grey and white matter tissue maps across all included  
16 subjects. The resulting two average images of grey and white matter were summed up to create a single  
17 mask. Whole-brain analyses were again thresholded at a voxel level of  $p < .05$ , family-wise error (FWE)-  
18 corrected for multiple comparisons within the whole-brain mask.


### 19 *Interactions of treatment and individual difference variables*

20 Similar to the approach used for response times, we explored interactions of treatment and individual  
21 differences in age, IQ, anxiety, depression, autistic traits, empathy and alexithymia on reward related  
22 brain activation in the regions of interest for the anticipation and outcome phases. For the anticipation  
23 phase, we extracted average contrast estimates for money: reward > no reward and social: reward > no  
24 reward from the left and right ventral striatum. This was done separately for oxytocin and placebo  
25 sessions. Next, all individual difference variables were correlated with average contrast estimates under  
26 oxytocin and placebo using Spearman's rho. Again, for each variable of interest, the resulting two  
27 correlation coefficients were then compared using the approach for dependent overlapping correlations  
28 proposed by Steiger [71] as implemented in the cocor R package [72]. The same procedure was used  
29 for the outcome phase, where contrast estimates were extracted from the left and right amygdala.

30

## 1 Results

### 2 Behavioral data



**Figure 2:** Mean response times for each task type and level of reward intensity. On average, response times were faster when participants anticipated reward compared to no reward. There were no significant differences between the ASD group and control group and no effects of treatment on mean response times.

3 Mean hit rates for all task conditions ranged from 63,3% to 66,0% (supplementary Table S2), indicating  
4 successful adaptation of task difficulty to subjects' individual response times. A repeated-measures GLM  
5 revealed a significant main effect of reward intensity on log-transformed mean response times ( $F(1,67)$   
6 = 20.61,  $p < .001$ ,  $\eta_p^2 = .235$ ), with faster responses during the anticipation of reward ( $M = 307$ ,  $SD =$   
7 43.6 ms) compared to no reward ( $M = 315$ ,  $SD = 48.4$  ms). There were no significant main effects of  
8 group or treatment and no significant interaction effects. Differences in age, IQ, anxiety, depression,  
9 autistic traits, empathy, and alexithymia did not significantly moderate treatment effects on reward  
10 sensitivity across groups (supplementary Figure S3, supplementary Table S3).

11 However, treatment influenced state anxiety during the two study visits. There was a significant main  
12 effect of treatment ( $F(1,67) = 4.01$ ,  $p = .049$ ,  $\eta_p^2 = .056$ ) and a significant interaction of treatment and  
13 arm ( $F(1,67) = 5.78$ ,  $p = .019$ ,  $\eta_p^2 = .079$ ). Post-hoc t-tests revealed significant differences in STAI-S  
14 sum scores only in the group that received placebo first. Here, anxiety was lower after participants  
15 received oxytocin (second session,  $M = 31.9$ ,  $SD = 5.76$ ) as compared to placebo (first session,  $M =$   
16 33.5,  $SD = 7.20$ ,  $t(67) = 3.19$ ,  $p = .013$ , corrected for multiple comparisons using Holm's procedure [83]).  
17 There was no such effect in the group that received oxytocin first (oxytocin:  $M = 33.4$ ,  $SD = 7.57$ ,




1 placebo:  $M = 33.1$ ,  $SD = 8.17$ ,  $p > .05$ ). Further, there was a main effect of time ( $F(1,67) = 5.58$ ,  $p =$   
2  $.021$ ,  $\eta_p^2 = .077$ ), indicating that participants felt more anxious before MRI scanning than after scanning  
3 (pre:  $M = 34.0$ ,  $SD = 6.98$ ; post:  $M = 32.6$ ,  $SD = 7.09$ ). A main effect of group ( $F(1,67) = 8.24$ ,  $p = .005$ ,  
4  $\eta_p^2 = .110$ ) indicated that the ASD patients felt more anxious than control participants (ASD:  $M = 35.4$ ,  
5  $SD = 7.46$ ; control:  $M = 31.1$ ,  $SD = 4.97$ ).

6 Participants could not identify above chance level which nasal spray they received: 51.5% of participants  
7 correctly identified oxytocin ( $p = .904$ , Bayes factor<sub>10</sub> = 0.155) and 53.7% of participants correctly  
8 identified placebo nasal spray ( $p = .625$ , Bayes factor<sub>10</sub> = 0.182).

9 *Imaging data*

10 *Anticipation phase*



**Figure 3:** Ventral striatum activation during the reward anticipation phase. *A:* The anticipation phase was defined as the time interval within each trial between the start of the cue presentation and the target. *B:* Regions of interest for the ventral striatum (top left) and mean contrast estimates for ASD patients and control participants. Contrast estimates for each contrast of interest were extracted from 8mm spheres around peak coordinates from a meta-analysis examining reward anticipation in the ventral striatum [78]. There were no statistically significant differences between patients and controls, and no significant effects of treatment on task related activation. VS = ventral striatum, CG = control group.

1

2 For the anticipation phase, we first analyzed task related activation of the left and right ventral striatum

3 (Fig. 3). All cues induced significant ventral striatum activation compared to baseline (supplementary

4 Figure S4). However, on average, difference contrasts of interest (social > money, reward > no reward,

5 task × intensity) were not associated with ventral striatum activation. There were no significant

6 differences between patients and control participants in the placebo condition for all contrasts of interest.

7 Further, treatment did not significantly influence task related activation in the ventral striatum and there

8 were no significant group × treatment interactions (Fig. 3). Whole-brain analyses revealed significant

9 average task effects in the occipital cortex and fusiform gyrus for social > money and reward > no reward


1 (supplementary Table S4). There were no significant group differences, effects of treatment, or group ×  
2 treatment interactions on whole-brain activation.

3 In an exploratory analysis, we examined whether individual differences in age, IQ, mental health, and  
4 personality moderated the effects of oxytocin treatment on reward sensitivity in the ventral striatum.  
5 Social anxiety (SIAS), autistic traits (AQ), depression (BDI-II) and alexithymia (TAS-20, but not BVAQ)  
6 showed significantly different correlations with monetary reward sensitivity after oxytocin compared to  
7 placebo ( $p$ s < .05, uncorrected; see supplementary Table S5). More precisely, after oxytocin, individuals  
8 with higher levels of self-reported social anxiety, depression, alexithymia, and autistic traits experienced  
9 higher ventral striatum activation in response to monetary reward cues than individuals scoring low on  
10 these traits ( $p$ s = .157 - .383). Under the placebo condition, there was mostly a negative association  
11 between these traits and reward sensitivity ( $p$ s = -.205 – -.020). However, none of these traits moderated  
12 treatment effects on social reward sensitivity.

### 13 *Outcome phase*

14 For the outcome phase, we first examined task related activation within the left and right amygdala (Fig.  
15 4). On average, the contrasts reward > no reward and social > money were associated with increased  
16 activation of the amygdala during hit trials. There were no significant differences between patients and  
17 control participants in the placebo condition for all contrasts of interest (Fig. 4). Treatment had a  
18 significant effect on the interaction of task and intensity in a single voxel within the left amygdala (MNI  
19 coordinates: -21, -4, -25,  $p$ (FWE)= .031): compared to placebo, oxytocin enhanced this interaction  
20 effect, suggesting that oxytocin led to an increase in differential reward sensitivity for social compared  
21 to monetary cues. There were no significant group × treatment interactions on task related amygdala  
22 responses. Whole-brain analyses further revealed widespread average task related activation of  
23 occipital and superior parietal regions for reward > no reward, occipital and superior parietal regions,  
24 orbitofrontal cortex, dorsomedial prefrontal cortex and midbrain structures for social > money, and  
25 occipital regions, fusiform gyrus, precuneus and superior parietal regions for the interaction of task and

1 intensity (supplementary Table S6). There were no significant group differences, effects of treatment, or  
 2 group  $\times$  treatment interactions on whole-brain activation.  
 3 Again, we explored whether individual differences in age, IQ, mental health, and personality moderated  
 4 the effects of oxytocin treatment on reward sensitivity in the amygdala. There were no significant  
 5 differences between correlations of all individual difference variables and reward sensitivity after



**Figure 4:** Task related amygdala activation during the outcome phase of hit trials. *A:* The outcome phase within a trial. We only analyzed hit trials, i.e. trials with sufficiently fast responses. *B:* Regions of interest for the amygdala (top left) and mean contrast estimates for ASD patients and control participants. There were no statistically significant differences between patients and controls. CG = control group.

6 oxytocin and placebo, suggesting that age, IQ, mental health, and personality did not moderate oxytocin  
 7 effects on amygdala responsiveness to rewards (supplementary Table S7).

## 8 Discussion

1 The aim of this randomized controlled trial was to examine acute effects of intranasal oxytocin on the  
2 neural correlates of reward processing in male participants with ASD and healthy male control  
3 participants. Using a well-established fMRI task, we did not find support for the notion that oxytocin  
4 substantially influences brain activation related to reward anticipation or consumption, neither in ASD  
5 nor in control participants. Of all analyses across different a-priori specified regions of interest and two  
6 task phases, only one contrast yielded a statistically significant effect of oxytocin on brain activation.  
7 Further, under placebo there were no statistically significant differences in reward related brain function  
8 between subjects with and without ASD. Exploratory analyses suggested that oxytocin might increase  
9 ventral striatum sensitivity to monetary rewards in individuals with high levels of self-reported anxiety,  
10 depression, alexithymia, and autistic traits.

11 The only oxytocin effect that could be detected was an enhancement of left amygdala responsiveness  
12 to the presentation of social rewards in the outcome phase. More precisely, oxytocin enhanced the  
13 interaction of task and reward intensity across both groups in a single amygdala voxel. This means that  
14 after oxytocin, this area was more sensitive to differences between neutral and smiling faces, as  
15 compared to the difference between pictures of empty and full wallets. This result suggests a relative  
16 increase in sensitivity to the reward value of faces, but not an increase of activation in response to faces  
17 *per se*. A general oxytocin effect on amygdala activation during face processing has been shown in  
18 several studies in adults with and without ASD, which has been interpreted as a neural mechanism  
19 underlying oxytocin's anxiolytic effects [21,79,84–87]. While our findings do not point in the direction of  
20 a general enhancement of amygdala activation in response to faces, they can be interpreted as support  
21 for the social salience hypothesis of oxytocin, which states that oxytocin modulates orientation to  
22 relevant social cues [88]. However, it should be highlighted that this effect was only found within a single  
23 voxel, which of course only comprises a small area of the left amygdala. Due to this extremely  
24 circumscribed area, and since this effect was the only significant one in a series of comparisons across  
25 different task phases and regions, this result should be interpreted with caution.

26 Overall, the results from the present study are in line with current meta-analytic evidence suggesting  
27 that, on average, intranasal oxytocin only has small and sometimes non-significant effects on social  
28 cognition and social functioning in individuals with ASD [43,89]. This evidence is further supported by a  
29 recent large-scale clinical trial showing that daily administration of oxytocin did not significantly influence  
30 social behaviors in 106 men with ASD [90]. However, meta-analyses average across a wide range of

1 tasks and paradigms, which might mask highly context-specific effects of intranasal oxytocin that  
2 emerge through general mechanisms such as anxiety reduction [22,91]. Yet, our findings conflict with  
3 results from previous neuroimaging studies highlighting the potential of intranasal oxytocin to influence  
4 regions within the brain's reward circuit in individuals with and without ASD [26–29,47,48].

5 The predominant absence of statistically significant oxytocin effects on brain function could be due to  
6 several factors. For example, considering that there is strong evidence linking endogenous oxytocin to  
7 reward processing and motivation [23,24,92], one might argue that the method used for administering  
8 oxytocin is not ideal. Although some studies suggest that oxytocin is effectively delivered to the brain  
9 after intranasal administration [93,94], it has been debated whether the widely used dosage of 24 IU  
10 and administration by conventional nasal spray devices are optimal in this regard [95,96]. Possibly,  
11 indirect methods of increasing endogenous oxytocin levels, such as the administration of selective  
12 melanocortin receptor agonists [97], or the application of oxytocin metabolites [98] could lead to stronger  
13 effects than intranasal application. However, the dosage and form of administration used in the current  
14 study are identical to those used in previous studies showing an effect of oxytocin on reward processing  
15 in individuals with and without ASD [27–29,48]. Moreover, while oxytocin did not influence task-related  
16 behavior and brain activation in the current study, we did find a significant anxiolytic effect after oxytocin  
17 compared to placebo, indicating that oxytocin indeed reached the brain after administration. It is  
18 therefore unlikely that the absence of statistically significant oxytocin effects is solely related to details  
19 of the administration protocol.

20 Another possibility is that intranasal oxytocin effects are tied to specifics of the applied reward task,  
21 which could also explain the heterogeneity of the results in oxytocin trials examining reward processing  
22 and related brain activation in ASD. To date, only two other neuroimaging studies have examined  
23 oxytocin effects on reward processing in ASD, and both used conceptually different approaches. While  
24 the first study [48] used an incentive delay task, participants of the second study [47] performed a  
25 reinforcement learning task. Because of methodological similarities, one might expect the results from  
26 the current study to be in line with results from the first study using the incentive delay task. However,  
27 even though the monetary or social incentive delay task is one of the most often used tasks to examine  
28 reward processing [77], several variations exist that may influence the magnitude of potential oxytocin  
29 effects. For example, the choice of stimuli (showing the amount of money won in numbers [48] vs.  
30 pictures of money, smiling vs. laughing faces) could influence the perceived value of the rewards and

1 the subjective relevance of the task. Since it has been discussed that oxytocin modulates stimulus  
2 processing depending on personal relevance of the stimuli [99], different experimental designs may lead  
3 to different results with regards to the oxytocin effects. However, due to the current scarcity of clinical  
4 studies investigating oxytocin effects on reward processing in ASD, we can only speculate about the  
5 influence of experimental design on the respective outcomes at this point.

6 Another reason for the predominant absence of general oxytocin effects might be related to an  
7 overestimation of effect sizes based on early oxytocin trials. Only a few years ago, oxytocin seemed to  
8 be a highly promising treatment option for ASD, with an estimated combined effect size of  $d=0.57$  [100].  
9 Subsequent studies examining the effects of intranasal oxytocin on social cognition and behavior have  
10 however produced inconsistent results, and some of the earlier studies could not be replicated [101–  
11 103]. Recent research indicates that the median effect size across human oxytocin studies is 0.14, and  
12 most studies examining intranasal oxytocin interventions do not have sufficiently large samples to  
13 reliably detect effects of this magnitude [104]. Although our sample is considerably larger than the  
14 average sample size in oxytocin intervention studies with neurodevelopmental disorders (27.4  
15 participants on average [89]), this suggests that the problem of data insensitivity might also be present  
16 in the current sample. However, previous studies on reward-related brain function have shown oxytocin  
17 effects even in samples of 15 [47] and 28 [48] individuals with ASD. If these results reflect true effects  
18 of oxytocin treatment on reward processing with roughly accurate effect size estimates, we would also  
19 expect to see effects in our sample.

20 While intranasal oxytocin did not have significant effects on reward-related brain function on average,  
21 our results suggest that oxytocin efficacy is influenced by individual differences in autistic traits, anxiety,  
22 depression, and alexithymia during monetary reward anticipation. After oxytocin administration,  
23 individuals with higher levels of self-reported social anxiety, depression, alexithymia, and autistic traits  
24 showed higher ventral striatum activation in response to monetary cues than individuals scoring low on  
25 these traits. Although this contradicts our hypothesis of oxytocin effectiveness specifically in the social  
26 domain, this finding fits well with accounts stating that oxytocin effects depend on personality and other  
27 individual factors [91]. Along these lines, previous studies have identified social anxiety [105],  
28 alexithymia [106–108] and autistic traits [109,110] as potential moderating factors, which has  
29 strengthened the hope that intranasal oxytocin may be specifically effective in individuals with a  
30 diagnosis of mental disorder. However, when we examined group  $\times$  treatment interactions on reward-

1 related brain activation in the present study, there were no significant differences between the control  
2 and ASD groups in terms of oxytocin effects. The absence of significant group  $\times$  treatment interactions  
3 is surprising considering that on average, the ASD group showed significantly higher scores for autistic  
4 traits, anxiety, depression, and alexithymia than the control group, which is comparable to findings from  
5 previous clinical studies [107,108,111]. Since these results are based on an exploratory approach, it will  
6 be up to future studies to evaluate the robustness of the modulatory effects of these traits, and to uncover  
7 possible reasons for the associations between these social traits and reward sensitivity in a non-social  
8 domain.

9 In addition to the absence of significant group  $\times$  treatment interactions, we did not find significant  
10 differences between the two groups under placebo, neither during the anticipation nor the consumption  
11 of social and monetary rewards. This result stands in contrast to a hypothesized social “wanting”  
12 dysfunction underlying autistic symptoms [6], which posits atypical reward processing specifically during  
13 the anticipation of social rewards. This supposed deficit is at the heart of accounts depicting autism as  
14 an “extreme case of diminished social motivation” [112]. However, results from previous neuroimaging  
15 studies using a monetary and/or social incentive delay task do not support the notion of a social wanting  
16 dysfunction. While two studies showed reward circuit hypoactivation especially during the anticipation  
17 and receipt of monetary but not social rewards [113,114], one study showed hypoactivation only during  
18 the receipt of social rewards, which corresponds to social “liking” [115]. None of these studies reported  
19 pronounced hypoactivation of the reward circuit during social reward anticipation, that is, social  
20 “wanting”, in individuals with ASD. These contrary findings are accompanied by criticisms of the social  
21 motivation hypothesis, demonstrating that this assumption is contradicted by the testimony of individuals  
22 with ASD, and that it often has negative effects on autism research and the development of treatments  
23 [116]. Thus, reducing difficulties in social communication and interaction in ASD to disrupted reward-  
24 seeking tendencies in social contexts dismisses the inconsistencies within the neuroscientific literature  
25 on reward processing, and might be harmful to individuals with an ASD diagnosis.

26 Our results are also in contrast to meta-analytic evidence showing a broader range of atypical reward  
27 processing in ASD [14]. A possible explanation is that atypical reward processing is not universally linked  
28 to the pathology of ASD, but rather depends on certain individual factors that cannot be assessed in our  
29 relatively homogeneous all-male adult sample. For example, it has been discussed that autistic children  
30 and adolescents might show a more pronounced alteration of striatal activation during social reward



1 tasks compared to adults [14], which aligns well with results from studies examining reward processing  
2 in adolescents without an ASD diagnosis [117]. Further, more severe autistic symptoms seem to be  
3 linked to greater caudate hypoactivation [14]. This could explain the absence of statistically significant  
4 differences between our ASD group with relatively mild symptoms and the age- and IQ-matched control  
5 group. Taken together, the findings of our study challenge the assumption that atypical reward  
6 processing is a primary cause behind social difficulties in ASD. Instead, it seems likely that individual  
7 differences in reward processing exist across autistic and non-autistic individuals alike.

## 8 **Conclusions**

9 Overall, our results do not support the hypothesis that intranasal oxytocin generally enhances activation  
10 of reward-related neural circuits in men with and without ASD. In line with recent evidence, the effects  
11 of intranasal oxytocin are likely too subtle to fundamentally shape reward circuitry regardless of context.  
12 Instead, oxytocin efficacy may be influenced by features of the experimental design, as well as individual  
13 differences in autistic traits, depression, anxiety, and alexithymia irrespective of an ASD diagnosis,  
14 especially for non-social rewards. Moreover, our results raise doubts about the hypothesis that reward  
15 processing is universally altered in ASD. In light of these findings, the use of oxytocin to improve social  
16 reward processing does not appear to be a promising avenue for improving social difficulties in ASD.

17

## 18 **Acknowledgements**

19 We would like to thank Johanna Klose, Kerstin Neubauer, Franca Schwesinger, Katharina Ohm, Sarah  
20 Rösch and Lisa Nix for their help as student assistants; Janine Baumann, Nora Czekalla, Jöran Lepsien,  
21 Toralf Mildner, André Pampel, Manuela Hofmann, Sylvie Neubert, Mandy Jochemko, Anke Kummer,  
22 Simone Wipper, Nicole Pampus and Domenica Klank for their assistance in neuroimaging; David Stolz,  
23 Laura Müller-Pinzler and Martin Göttlich for their assistance during programming and data analysis;  
24 Norbert Brüggemann, Henrike Hanßen, and Anna Kosatschek for their assistance as study physicians;  
25 Natalia Chechko, Susanne Stickel (Aachen), Gerti Gerber (Marburg), Daniel Alvarez-Fischer, Veronika  
26 Thorns (Lübeck), Stefan Ehrlich, and Veit Rössner (Dresden) for their efforts during participant  
27 recruitment; Henrik Grunert and Kerstin Traeger for technical assistance; Matthias Collier, Kathrin  
28 Scheibe and Silke Hauer from the Clinical Trial Centre Leipzig who provided data management tools

1 and randomization; and Anne-Kathrin Wermter for her kind assistance during the preparation of this  
2 study.

### 3 **Funding**

4 This clinical trial was part of the ASD-Net, the German consortium for Autism Spectrum Disorder, and  
5 was funded by the German Federal Ministry of Education and Research (BMBF, grant numbers:  
6 01EE1409H and 01EE1409I). Funding period: 2015–2019.

7 Parts of the study were performed, and MRI data were assessed at the former department of Social  
8 Neuroscience at the Max Planck Institute for Human Cognitive and Brain Sciences Leipzig (MPI-CBS)  
9 headed by Prof. Dr. Tania Singer until 2018. Funding required for neuroimaging, the support team (e.g.,  
10 technical, imaging, physician, recruitment) and some of the researchers (Kanske, Engert) during that  
11 period was provided by Tania Singer's budget she received as director of the department of Social  
12 Neuroscience by the Max Planck Society.

### 13 **Data availability**

14 The datasets generated and analyzed during the current study are not publicly available due to them  
15 containing information that could compromise research participant privacy and consent. Fully  
16 anonymized data are available from the corresponding author on reasonable request.

## 1   **References**

- 2   1.    Senju A, Johnson MH. Atypical eye contact in autism: Models, mechanisms and development.  
3        *Neurosci Biobehav Rev.* 2009;33:1204–1214.
- 4   2.    Baron-Cohen S. Perceptual role taking and protodeclarative pointing in autism. *Br J Dev Psychol.*  
5        1989;7:113–127.
- 6   3.    Wetherby AM, Watt N, Morgan L, Shumway S. Social communication profiles of children with  
7        autism spectrum disorders late in the second year of life. *J Autism Dev Disord.* 2007;37:960–  
8        975.
- 9   4.    Daniel LS, Billingsley BS. What boys with an autism spectrum disorder say about establishing  
10       and maintaining friendships. *Focus Autism Other Dev Disabl.* 2010;25:220–229.
- 11 5.    Dawson G, Webb SJ, Wijsman E, Schellenberg G, Estes A, Munson J, et al. Neurocognitive and  
12        electrophysiological evidence of altered face processing in parents of children with autism:  
13        Implications for a model of abnormal development of social brain circuitry in autism. *Dev*  
14        *Psychopathol.* 2005;17:679–697.
- 15 6.    Kohls G, Chevallier C, Troiani V, Schultz RT. Social ‘wanting’ dysfunction in autism:  
16        neurobiological underpinnings and treatment implications. *J Neurodev Disord.* 2012;4:10.
- 17 7.    Hedger N, Dubey I, Chakrabarti B. Social orienting and social seeking behaviors in ASD. A meta  
18        analytic investigation. *Neurosci Biobehav Rev.* 2020;119:376–395.
- 19 8.    Garretson HB, Fein D, Waterhouse L. Sustained attention in children with autism. *J Autism Dev*  
20        *Disord.* 1990;20:101–114.
- 21 9.    Geurts HM, Luman M, van Meel CS. What’s in a game: the effect of social motivation on  
22        interference control in boys with ADHD and autism spectrum disorders. *J Child Psychol*  
23        *Psychiatry.* 2008;49:848–857.
- 24 10.   Demurie E, Roeyers H, Baeyens D, Sonuga-Barke E. Common alterations in sensitivity to type  
25        but not amount of reward in ADHD and autism spectrum disorders. *J Child Psychol Psychiatry.*  
26        2011;52:1164–1173.
- 27 11.   Sepeta L, Tsuchiya N, Davies MS, Sigman M, Bookheimer SY, Dapretto M. Abnormal social  
28        reward processing in autism as indexed by pupillary responses to happy faces. *J Neurodev*  
29        *Disord.* 2012;4:0.
- 30 12.   Ruta L, Famà FI, Bernava GM, Leonardi E, Tartarisco G, Falzone A, et al. Reduced preference  
31        for social rewards in a novel tablet based task in young children with Autism Spectrum Disorders.  
32        *Sci Rep.* 2017;7:3329.
- 33 13.   Bottini S. Social reward processing in individuals with autism spectrum disorder: A systematic  
34        review of the social motivation hypothesis. *Res Autism Spectr Disord.* 2018;45:9–26.

- 1 14. Clements CC, Zoltowski AR, Yankowitz LD, Yerys BE, Schultz RT, Herrington JD. Evaluation of  
2 the social motivation hypothesis of autism a systematic review and meta-analysis. *JAMA*  
3 *Psychiatry*. 2018;75:797–808.
- 4 15. Haber SN, Knutson B. The reward circuit: Linking primate anatomy and human imaging.  
5 *Neuropsychopharmacology*. 2010;35:4–26.
- 6 16. O’Doherty JP, Deichmann R, Critchley HD, Dolan RJ. Neural responses during anticipation of a  
7 primary taste reward. *Neuron*. 2002;33:815–826.
- 8 17. Liljeholm M, O’Doherty JP. Contributions of the striatum to learning, motivation, and  
9 performance: An associative account. *Trends Cogn Sci*. 2012;16:467–475.
- 10 18. Meyer-Lindenberg A, Domes G, Kirsch P, Heinrichs M. Oxytocin and vasopressin in the human  
11 brain: Social neuropeptides for translational medicine. *Nat Rev Neurosci*. 2011;12:524–538.
- 12 19. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans.  
13 *Nature*. 2005;435:673–676.
- 14 20. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC. Oxytocin improves ‘mind-reading’ in  
15 humans. *Biol Psychiatry*. 2007;61:731–733.
- 16 21. Petrovic P, Kalisch R, Singer T, Dolan RJ. Oxytocin Attenuates Affective Evaluations of  
17 Conditioned Faces and Amygdala Activity. *J Neurosci*. 2008;28:6607– 6615.
- 18 22. Singer T, Snozzi R, Bird G, Petrovic P, Silani G, Heinrichs M, et al. Effects of oxytocin and  
19 prosocial behavior on brain responses to direct and vicariously experienced pain. *Emotion*.  
20 2008;8:781–791.
- 21 23. Dölen G, Darvishzadeh A, Huang KW, Malenka RC. Social reward requires coordinated activity  
22 of nucleus accumbens oxytocin and serotonin. *Nature*. 2013;501:179–184.
- 23 24. Hung LW, Neuner S, Polepalli JS, Beier KT, Wright M, Walsh JJ, et al. Gating of social reward  
24 by oxytocin in the ventral tegmental area. *Science*. 2017;357:1406–1411.
- 25 25. Xiao L, Priest MF, Nasenbeny J, Lu T, Kozorovitskiy Y. Biased Oxytocinergic Modulation of  
26 Midbrain Dopamine Systems. *Neuron*. 2017;95:368-384.e5.
- 27 26. Groppe SE, Gossen A, Rademacher L, Hahn A, Westphal L, Gründer G, et al. Oxytocin  
28 influences processing of socially relevant cues in the ventral tegmental area of the human brain.  
29 *Biol Psychiatry*. 2013;74:172–179.
- 30 27. Mickey BJ, Heffernan J, Heisel C, Peciña M, Hsu DT, Zubieta JK, et al. Oxytocin modulates  
31 hemodynamic responses to monetary incentives in humans. *Psychopharmacology (Berl)*.  
32 2016;233:3905–3919.
- 33 28. Li T, Chen X, Mascaró J, Haroon E, Rilling JK. Intranasal oxytocin, but not vasopressin,  
34 augments neural responses to toddlers in human fathers. *Horm Behav*. 2017;93:193–202.

- 1 29. Striepens N, Matusch A, Kendrick KM, Mihov Y, Elmenhorst D, Becker B, et al. Oxytocin  
2 enhances attractiveness of unfamiliar female faces independent of the dopamine reward system.  
3 *Psychoneuroendocrinology*. 2014;39:74–87.
- 4 30. Boccia ML, Petrusz P, Suzuki K, Marson L, Pedersen CA. Immunohistochemical localization of  
5 oxytocin receptors in human brain. *Neuroscience*. 2013;253:155–164.
- 6 31. Quintana DS, Rokicki J, van der Meer D, Alnæs D, Kaufmann T, Córdova-Palomera A, et al.  
7 Oxytocin pathway gene networks in the human brain. *Nat Commun*. 2019;10:668.
- 8 32. Mccall C, Singer T. The animal and human neuroendocrinology of social cognition, motivation  
9 and behavior. *Nat Neurosci*. 2012;15:681–688.
- 10 33. Quattrocki E, Friston K. Autism, oxytocin and interoception. *Neurosci Biobehav Rev*.  
11 2014;47:410–430.
- 12 34. Modahl C, Green L, Fein D, Morris M, Waterhouse L, Feinstein C, et al. Plasma oxytocin levels  
13 in autistic children. *Biol Psychiatry*. 1998;43:270–277.
- 14 35. Al-Ayadhi LY. Altered oxytocin and vasopressin levels in autistic children in Central Saudi Arabia.  
15 *Neurosciences*. 2005;10:47–50.
- 16 36. Kobylinska L, Panaitescu AM, Gabreanu G, Anghel CG, Mihailescu I, Rad F, et al. Plasmatic  
17 levels of neuropeptides, including oxytocin, in children with autism spectrum disorder, correlate  
18 with the disorder severity. *Acta Endocrinol (Copenh)*. 2019;15:16–24.
- 19 37. Bakker-Huvenaars MJ, Greven CU, Herpers P, Wieggers E, Jansen A, van der Steen R, et al.  
20 Saliva oxytocin, cortisol, and testosterone levels in adolescent boys with autism spectrum  
21 disorder, oppositional defiant disorder/conduct disorder and typically developing individuals. *Eur*  
22 *Neuropsychopharmacol*. 2020;30:87–101.
- 23 38. Miller M, Bales KL, Taylor SL, Yoon J, Hostetler CM, Carter CS, et al. Oxytocin and vasopressin  
24 in children and adolescents with autism spectrum disorders: Sex differences and associations  
25 with symptoms. 2013;6:91–102.
- 26 39. Parker KJ, Garner JP, Libove RA, Hyde SA, Hornbeak KB, Carson DS, et al. Plasma oxytocin  
27 concentrations and OXTR polymorphisms predict social impairments in children with and without  
28 autism spectrum disorder. *Proc Natl Acad Sci*. 2014;111:12258–12263.
- 29 40. Wilczyński KM, Siwiec A, Janas-Kozik M. Systematic review of literature on single-nucleotide  
30 polymorphisms within the oxytocin and vasopressin receptor genes in the development of social  
31 cognition dysfunctions in individuals suffering from autism spectrum disorder. *Front Psychiatry*.  
32 2019;10:380.
- 33 41. LoParo D, Waldman ID. The oxytocin receptor gene (OXTR) is associated with autism spectrum  
34 disorder: A meta-analysis. *Mol Psychiatry*. 2015;20:640–646.
- 35 42. Kranz TM, Kopp M, Waltes R, Sachse M, Duketis E, Jarczok TA, et al. Meta-analysis and

- 1 association of two common polymorphisms of the human oxytocin receptor gene in autism  
2 spectrum disorder. *Autism Res.* 2016;9:1036–1045.
- 3 43. Wang Y, Wang MJ, Rong Y, He HZ, Yang CJ. Oxytocin therapy for core symptoms in autism  
4 spectrum disorder: An updated meta-analysis of randomized controlled trials. *Res Autism Spectr*  
5 *Disord.* 2019;64:63–75.
- 6 44. Mayer A V, Wermter AK, Stroth S, Alter P, Haberhausen M, Stehr T, et al. Neural Activation of  
7 Empathy and The Role of Oxytocin and OXTR in Autism: A Randomized Controlled Trial.  
8 *Manuscr Submitt Publ.* 2021.
- 9 45. Gordon I, Vander Wyk BC, Bennett RH, Cordeaux C, Lucas M V., Eilbott JA, et al. Oxytocin  
10 enhances brain function in children with autism. *Proc Natl Acad Sci U S A.* 2013;110:20953–  
11 20958.
- 12 46. Gordon I, Jack A, Pretzsch CM, Vander Wyk B, Leckman JF, Feldman R, et al. Intranasal  
13 Oxytocin Enhances Connectivity in the Neural Circuitry Supporting Social Motivation and Social  
14 Perception in Children with Autism. *Sci Rep.* 2016;6:1–14.
- 15 47. Kruppa JA, Gossen A, Oberwelland Weiß E, Kohls G, Großheinrich N, Cholemkery H, et al.  
16 Neural modulation of social reinforcement learning by intranasal oxytocin in male adults with  
17 high-functioning autism spectrum disorder: a randomized trial. *Neuropsychopharmacology.*  
18 2019;44:749–756.
- 19 48. Greene RK, Spanos M, Alderman C, Walsh E, Bizzell J, Mosner MG, et al. The effects of  
20 intranasal oxytocin on reward circuitry responses in children with autism spectrum disorder. *J*  
21 *Neurodev Disord.* 2018;10:1–16.
- 22 49. Rademacher L, Krach S, Kohls G, Irmak A, Gründer G, Spreckelmeyer KN. Dissociation of neural  
23 networks for anticipation and consumption of monetary and social rewards. *Neuroimage.*  
24 2010;49:3276–3285.
- 25 50. Spreckelmeyer KN, Krach S, Kohls G, Rademacher L, Irmak A, Konrad K, et al. Anticipation of  
26 monetary and social reward differently activates mesolimbic brain structures in men and women.  
27 *Soc Cogn Affect Neurosci.* 2009;4:158–165.
- 28 51. Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward  
29 selectively recruits nucleus accumbens. *J Neurosci.* 2001;21:RC159.
- 30 52. Preckel K, Kanske P, Singer T, Paulus FM, Krach S. Clinical trial of modulatory effects of oxytocin  
31 treatment on higher-order social cognition in autism spectrum disorder: a randomized, placebo-  
32 controlled, double-blind and crossover trial. *BMC Psychiatry.* 2016;16:329.
- 33 53. Kamp-Becker I, Poustka L, Bachmann C, Ehrlich S, Hoffmann F, Kanske P, et al. Study protocol  
34 of the ASD-Net, the German research consortium for the study of Autism Spectrum Disorder  
35 across the lifespan: From a better etiological understanding, through valid diagnosis, to more  
36 effective health care. *BMC Psychiatry.* 2017;17:1–14.

- 1 54. Wechsler D. Wechsler Adult Intelligence Scale—Fourth Edition. San Antonio, TX: Pearson  
2 Assessment; 2008.
- 3 55. Lord C, Risi S, Lambrecht L, Cook EH, Leventhal BL, DiLavore PC, et al. Autism Diagnostic  
4 Observation Schedule (ADOS). *J Autism Dev Disord.* 2000. 2000.  
5 <https://doi.org/10.1007/BF02211841>.
- 6 56. Rutter M, Le Couteur A, Lord C. Autism Diagnostic Interview-Revised (ADI-R). Los Angeles:  
7 Western Psychological Services; 2003.
- 8 57. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The Autism-Spectrum Quotient  
9 (AQ): Evidence from Asperger syndrome/high-functioning autism, males and females, scientists  
10 and mathematicians. *J Autism Dev Disord.* 2001;31:5–17.
- 11 58. Bach M, Bach D, de Zwaan M, Serim M, Böhmer F. Validation of the German version of the 20-  
12 item Toronto Alexithymia Scale in normal persons and psychiatric patients. *Psychother*  
13 *Psychosom Med Psychol.* 1996;46:23–28.
- 14 59. Bagby RM, Parker JDA, Taylor GJ. The twenty-item Toronto Alexithymia scale—I. Item selection  
15 and cross-validation of the factor structure. *J Psychosom Res.* 1994;38:23–32.
- 16 60. Beck AT, Steer RA, Brown GK. Beck Depression Inventory (BDI-II). 2nd ed. San Antonio, TX:  
17 The Psychological Corporation; 1996.
- 18 61. Kühner C, Bürger C, Keller F, Hautzinger M. Reliabilität und Validität des revidierten Beck-  
19 Depressions-inventars (BDI-II). 2006. 2006. <https://doi.org/10.1007/s00115-006-2098-7>.
- 20 62. Laux L, Glanzmann P, Schaffner P, Spielberger CD. Das State-Trait-Angstinventar (STAI) :  
21 theoretische Grundlagen und Handanweisung. Weinheim: Beltz; 1981.
- 22 63. Davis MH. A multidimensional approach to individual differences in empathy. *J Pers Soc*  
23 *Psychol.* 1983;44:113–126.
- 24 64. Paulus C. Der Saarbrücker Persönlichkeitsfragebogen (SPF-IRI) zur Messung von Empathie.  
25 2009.
- 26 65. Mattick RP, Clarke JC. Development and validation of measures of social phobia scrutiny fear  
27 and social interaction anxiety. *Behav Res Ther.* 1998;36:455–470.
- 28 66. Vorst HCM, Bermond B. Validity and reliability of the Bermond-Vorst Alexithymia Questionnaire.  
29 *Pers Individ Dif.* 2001;30:413–434.
- 30 67. Tottenham N, Tanaka JW, Leon AC, McCarry T, Nurse M, Hare TA, et al. The NimStim set of  
31 facial expressions: Judgments from untrained research participants. *Psychiatry Res.*  
32 2009;168:242–249.
- 33 68. The jamovi project. Jamovi. 2019.
- 34 69. R Core Team. R: A language and environment for statistical computing. 2020.

- 1 70. Whelan R. Effective analysis of reaction time data. *Psychol Rec.* 2008;58:475–482.
- 2 71. Steiger JH. Tests for comparing elements of a correlation matrix. *Psychol Bull.* 1980;87:245–  
3 251.
- 4 72. Diedenhofen B, Musch J. cocor: A Comprehensive Solution for the Statistical Comparison of  
5 Correlations. *PLoS One.* 2015;10:e0121945.
- 6 73. The Wellcome Centre for Human Neuroimaging. SPM12 Software - Statistical Parametric  
7 Mapping. 2014.
- 8 74. The MathWorks Inc. MATLAB. 2019.
- 9 75. Diedrichsen J, Shadmehr R. Detecting and adjusting for artifacts in fMRI time series data.  
10 *Neuroimage.* 2005;27:624–634.
- 11 76. Wilson RP, Colizzi M, Bossong MG, Allen P, Kempton M, Abe N, et al. The Neural Substrate of  
12 Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay  
13 Task. *Neuropsychol Rev.* 2018;28.
- 14 77. Martins D, Rademacher L, Gabay AS, Taylor R, Richey JA, Smith DV, et al. Mapping social  
15 reward and punishment processing in the human brain: A voxel-based meta-analysis of  
16 neuroimaging findings using the Social Incentive Delay task. *Neurosci Biobehav Rev.*  
17 2021;122:1–17.
- 18 78. Diekhof EK, Kaps L, Falkai P, Gruber O. The role of the human ventral striatum and the medial  
19 orbitofrontal cortex in the representation of reward magnitude - An activation likelihood estimation  
20 meta-analysis of neuroimaging studies of passive reward expectancy and outcome processing.  
21 *Neuropsychologia.* 2012;50:1252–1266.
- 22 79. Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC. Oxytocin attenuates  
23 amygdala responses to emotional faces regardless of valence. *Biol Psychiatry.* 2007;62:1187–  
24 1190.
- 25 80. Domes G, Kumbier E, Heinrichs M, Herpertz SC. Oxytocin promotes facial emotion recognition  
26 and amygdala reactivity in adults with asperger syndrome. *Neuropsychopharmacology.*  
27 2014;39:698–706.
- 28 81. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al.  
29 Automated anatomical labeling of activations in SPM using a macroscopic anatomical  
30 parcellation of the MNI MRI single-subject brain. *Neuroimage.* 2002. 2002.  
31 <https://doi.org/10.1006/nimg.2001.0978>.
- 32 82. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and  
33 cytoarchitectonic atlas-based interrogation of fMRI data sets. *Neuroimage.* 2003;19:1233–1239.
- 34 83. Holm S. A simple sequentially rejective multiple test procedure. *Scand J Stat.* 1979;6:65–70.
- 35 84. Kirsch P. Oxytocin modulates neural circuitry for social cognition and fear in humans. *J Neurosci.*



- 1 2005;25:11489–11493.
- 2 85. Gamer M, Zurowski B, Büchel C. Different amygdala subregions mediate valence- related and  
3 attentional effects of oxytocin in humans. *Proc Natl Acad Sci.* 2010;107:9400–9405.
- 4 86. Domes G, Heinrichs M, Kumbier E, Grossmann A, Hauenstein K, Herpertz SC. Effects of  
5 intranasal oxytocin on the neural basis of face processing in autism spectrum disorder. *Biol*  
6 *Psychiatry.* 2013;74:164–171.
- 7 87. Hurlemann R, Patin A, Onur OA, Cohen MX, Baumgartner T, Metzler S, et al. Oxytocin enhances  
8 amygdala-dependent, socially reinforced learning and emotional empathy in humans. *J*  
9 *Neurosci.* 2010;30:4999–5007.
- 10 88. Shamay-Tsoory SG, Abu-Akel A. The social salience hypothesis of oxytocin. *Biol Psychiatry.*  
11 2016;79:194–202.
- 12 89. Keech B, Crowe S, Hocking DR. Intranasal oxytocin, social cognition and neurodevelopmental  
13 disorders: A meta-analysis. *Psychoneuroendocrinology.* 2018;87:9–19.
- 14 90. Yamasue H, Okada T, Munosue T, Kuroda M, Fujioka T, Uno Y, et al. Effect of intranasal oxytocin  
15 on the core social symptoms of autism spectrum disorder: a randomized clinical trial. *Mol*  
16 *Psychiatry.* 2020;25:1849–1858.
- 17 91. Bartz JA, Zaki J, Bolger N, Ochsner KN. Social effects of oxytocin in humans: Context and person  
18 matter. *Trends Cogn Sci.* 2011;15:301–309.
- 19 92. Love T. Oxytocin, motivation and the role of dopamine. *Pharmacology, Biochem Behav.*  
20 2014:49–60.
- 21 93. Tanaka A, Furubayashi T, Arai M, Inoue D, Kimura S, Kiriya A, et al. Delivery of Oxytocin to  
22 the Brain for the Treatment of Autism Spectrum Disorder by Nasal Application. *Mol Pharm.*  
23 2018;15:1105–1111.
- 24 94. Quintana DS, Smerud KT, Andreassen OA, Djupesland PG. Evidence for intranasal oxytocin  
25 delivery to the brain: Recent advances and future perspectives. *Ther Deliv.* 2018;9:515–525.
- 26 95. Quintana DS, Westlye LT, Hope S, Nærland T, Elvsåshagen T, Dørum E, et al. Dose-dependent  
27 social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in  
28 adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover  
29 trial. *Transl Psychiatry.* 2017;7:e1136.
- 30 96. Quintana DS, Westlye LT, Alnæs D, Rustan ØG, Kaufmann T, Smerud KT, et al. Low dose  
31 intranasal oxytocin delivered with Breath Powered device dampens amygdala response to  
32 emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI  
33 trial. *Psychoneuroendocrinology.* 2016;69:180–188.
- 34 97. Peñagarikano O, Lázaro MT, Lu X-H, Gordon A, Dong H, Lam HA, et al. Exogenous and evoked  
35 oxytocin restores social behavior in the *Cntnap2* mouse model of autism. *Sci Transl Med.*

- 1 2015;7:271–279.
- 2 98. Moy SS, Teng BL, Nikolova VD, Riddick N V., Simpson CD, Van Deusen A, et al. Prosocial  
3 effects of an oxytocin metabolite, but not synthetic oxytocin receptor agonists, in a mouse model  
4 of autism. *Neuropharmacology*. 2019;144:301–311.
- 5 99. Harari-Dahan O, Bernstein A. A general approach - avoidance hypothesis of Oxytocin:  
6 Accounting for social and non-social effects of oxytocin. *Neurosci Biobehav Rev*. 2014;47.
- 7 100. Bakermans-Kranenburg MJ, van IJzendoorn MH. Sniffing around oxytocin: review and meta-  
8 analyses of trials in healthy and clinical groups with implications for pharmacotherapy. *Transl*  
9 *Psychiatry*. 2013;3.
- 10 101. Lane A, Mikolajczak M, Treinen E, Samson D, Corneille O, De Timary P, et al. Failed replication  
11 of oxytocin effects on trust: The envelope task case. *PLoS One*. 2015;10:1–10.
- 12 102. Radke S, de Bruijn ERA. Does oxytocin affect mind-reading? A replication study.  
13 *Psychoneuroendocrinology*. 2015. 2015. <https://doi.org/10.1016/j.psyneuen.2015.06.006>.
- 14 103. Declerck CH, Boone C, Pauwels L, Vogt B, Fehr E. A registered replication study on oxytocin  
15 and trust. *Nat Hum Behav*. 2020:1–10.
- 16 104. Quintana DS. Most oxytocin administration studies are statistically underpowered to reliably  
17 detect (or reject) a wide range of effect sizes. *Compr Psychoneuroendocrinology*.  
18 2020;4:100014.
- 19 105. Kanat M, Spenthof I, Riedel A, Van Elst LT, Heinrichs M, Domes G. Restoring effects of oxytocin  
20 on the attentional preference for faces in autism. *Transl Psychiatry*. 2017. 2017.  
21 <https://doi.org/10.1038/tp.2017.67>.
- 22 106. Luminet O, Grynberg D, Ruzette N, Mikolajczak M. Personality-dependent effects of oxytocin:  
23 Greater social benefits for high alexithymia scorers. *Biol Psychol*. 2011;87:401–406.
- 24 107. Bird G, Silani G, Brindley R, White S, Frith U, Singer T. Empathic brain responses in insula are  
25 modulated by levels of alexithymia but not autism. *Brain*. 2010;133:1515–1525.
- 26 108. Silani G, Bird G, Brindley R, Singer T, Frith C, Frith U. Levels of emotional awareness and autism:  
27 An fMRI study. *Soc Neurosci*. 2008;3:97–112.
- 28 109. Scheele D, Kendrick KM, Khouri C, Kretzer E, Schläpfer TE, Stoffel-Wagner B, et al. An oxytocin-  
29 induced facilitation of neural and emotional responses to social touch correlates inversely with  
30 autism traits. *Neuropsychopharmacology*. 2014;39:2078–2085.
- 31 110. Xu L, Ma X, Zhao W, Luo L, Yao S, Kendrick KM. Oxytocin enhances attentional bias for neutral  
32 and positive expression faces in individuals with higher autistic traits.  
33 *Psychoneuroendocrinology*. 2015;62.
- 34 111. Bird G, Cook R. Mixed emotions: The contribution of alexithymia to the emotional symptoms of  
35 autism. *Transl Psychiatry*. 2013;3:285.

- 1 112. Chevallier C, Kohls G, Troiani V, Brodtkin ES, Schultz RT. The social motivation theory of autism.  
2 Trends Cogn Sci. 2012;16:231–239.
- 3 113. Dichter GS, Richey JA, Rittenberg AM, Sabatino A, Bodfish JW. Reward circuitry function in  
4 autism during face anticipation and outcomes. J Autism Dev Disord. 2012;42:147–160.
- 5 114. Dichter GS, Felder JN, Green SR, Rittenberg AM, Sasson NJ, Bodfish JW. Reward circuitry  
6 function in autism spectrum disorders. Soc Cogn Affect Neurosci. 2012;7:160–172.
- 7 115. Delmonte S, Balsters JH, McGrath J, Fitzgerald J, Brennan S, Fagan AJ, et al. Social and  
8 monetary reward processing in autism spectrum disorders. Mol Autism. 2012;3:7.
- 9 116. Jaswal VK, Akhtar N. Being versus appearing socially uninterested: Challenging assumptions  
10 about social motivation in autism. Behav Brain Sci. 2019;42:1–73.
- 11 117. Silverman MH, Jedd K, Luciana M. Neural networks involved in adolescent reward processing:  
12 An activation likelihood estimation meta-analysis of functional neuroimaging studies.  
13 Neuroimage. 2015;122:427–439.
- 14